These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis. Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515 [TBL] [Abstract][Full Text] [Related]
27. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior. DeWitt EM; Glick HA; Albert DA; Joffe MM; Wolfe F Arch Intern Med; 2006 Jan; 166(1):57-63. PubMed ID: 16401811 [TBL] [Abstract][Full Text] [Related]
30. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists. Gottlieb GS; Lesser CF; Holmes KK; Wald A Clin Infect Dis; 2003 Sep; 37(6):838-40. PubMed ID: 12955647 [TBL] [Abstract][Full Text] [Related]
31. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Gómez-Reino JJ; Carmona L; Angel Descalzo M; Arthritis Rheum; 2007 Jun; 57(5):756-61. PubMed ID: 17530674 [TBL] [Abstract][Full Text] [Related]
32. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349 [TBL] [Abstract][Full Text] [Related]
33. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. Delaunay C; Farrenq V; Marini-Portugal A; Cohen JD; Chevalier X; Claudepierre P J Rheumatol; 2005 Nov; 32(11):2183-5. PubMed ID: 16265699 [TBL] [Abstract][Full Text] [Related]
34. Arthralgia as an adverse event to infliximab: a reactive arthritis or triggering of psoriatic arthritis? Successful management by switching to etanercept. Moustou AE; Stratigos AJ; Vergou T; Gregoriou S; Georgala S; Danopoulou I J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):968-9. PubMed ID: 19207660 [No Abstract] [Full Text] [Related]
35. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2004 Aug; 53(30):683-6. PubMed ID: 15295313 [TBL] [Abstract][Full Text] [Related]
36. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Fautrel B; Sibilia J; Mariette X; Combe B; Ann Rheum Dis; 2005 Feb; 64(2):262-6. PubMed ID: 15184196 [TBL] [Abstract][Full Text] [Related]
37. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Askling J; Fored CM; Brandt L; Baecklund E; Bertilsson L; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Romanus V; Klareskog L; Feltelius N Arthritis Rheum; 2005 Jul; 52(7):1986-92. PubMed ID: 15986370 [TBL] [Abstract][Full Text] [Related]
38. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997 [TBL] [Abstract][Full Text] [Related]
39. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Hyrich KL; Symmons DP; Watson KD; Silman AJ; Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520 [TBL] [Abstract][Full Text] [Related]
40. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Wu E; Chen L; Birnbaum H; Yang E; Cifaldi M Curr Med Res Opin; 2008 Aug; 24(8):2229-40. PubMed ID: 18577308 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]